AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3045202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g/day) for 8 weeks followed by 1,25-(OH)2 vitamin D3 (0.5 micrograms/day) for 2 weeks
Number of subjects: 23
Study 3045202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus 1,25-(OH)2 vitamin D3
Number of subjects: 23
Study 30986442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 1817
Study 30986442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 3 mg
Number of subjects: 1817
Study 30986442 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg
Number of subjects: 1817
Study 30986442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 1817
Study 30986442 — intervention group
Group type: COMPARATOR
Intervention: Brolucizumab and Aflibercept
Number of subjects: 1817
Study 30672249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz TEAS combined with wristband pressing
Number of subjects: 80
Study 30672249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz TEAS combined with wristband pressing
Number of subjects: 80
Study 30672249 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS combined with wristband pressing
Number of subjects: 80
Study 30672249 — intervention group
Group type: COMPARATOR
Intervention: Postoperative routine care
Number of subjects: 80
Study 29138394 — intervention group
Group type: EXPERIMENTAL
Intervention: In silico system with a two-peak fitness landscape
Number of subjects: 0
Study 29138394 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic crossovers
Number of subjects: 0
Study 29138394 — intervention group
Group type: EXPERIMENTAL
Intervention: Population size
Number of subjects: 0
Study 29138394 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of genes
Number of subjects: 0
Study 25817323 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supervised therapy provided by a certified hand therapist (CHT)
Number of subjects: 50
Study 25817323 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program instructed and monitored by a certified hand therapist (CHT)
Number of subjects: 50
Study 23442554 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional arthroscopic partial meniscectomy
Number of subjects: 0
Study 23442554 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery procedure
Number of subjects: 0
Study 21228246 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin regimen (glargine once daily and glulisine before meals)
Number of subjects: 211
Study 21228246 — intervention group
Group type: COMPARATOR
Intervention: Sliding scale regular insulin (SSI) four times daily
Number of subjects: 211
Study 21228246 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin regimen
Number of subjects: 211
Study 21228246 — intervention group
Group type: COMPARATOR
Intervention: Sliding scale regular insulin (SSI)
Number of subjects: 211
Study 18820311 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind intra-articular injections (IAIs) in peripheral joints
Number of subjects: 96
Study 16801461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813
Study 16801461 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy alone (Control)
Number of subjects: 813
Study 16801461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with new-onset AF
Number of subjects: 813
Study 12717395 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT with liver involvement
Number of subjects: 95
Study 12717395 — intervention group
Group type: COMPARATOR
Intervention: HHT without liver involvement
Number of subjects: 95
Study 12717395 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis
Number of subjects: 95
Study 12717395 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 95
Study 11035135 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 (300 mg once daily)
Number of subjects: 20
Study 11035135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9385122 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 601
Study 9385122 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (all doses)
Number of subjects: 601
Study 9385122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 1539846 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA supplemented with a nighttime infusion of morphine 1.0 mg.h-1
Number of subjects: 156
Study 1539846 — intervention group
Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 156
Study 4002749 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (including autogenous training)
Number of subjects: 16
Study 4002749 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 16
Study 30895697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily in addition to standard care
Number of subjects: 4744
Study 30895697 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to standard care
Number of subjects: 4744
Study 27838760 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDCER informed consent form (ICF)
Number of subjects: 258
Study 27838760 — intervention group
Group type: COMPARATOR
Intervention: Conventional informed consent form (ICF)
Number of subjects: 258
Study 27325392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) + Contingency Management (CM)
Number of subjects: 159
Study 27325392 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) alone
Number of subjects: 159
Study 24535100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 73
Study 24535100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 23090521 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration
Number of subjects: 161
Study 23090521 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 161
Study 19527368 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for osteolymphoma (chemotherapy and radiotherapy)
Number of subjects: 25
Study 16430566 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled propofol 3 microg.ml(‐1) infusion
Number of subjects: 40
Study 16430566 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 1‐1.2% in air
Number of subjects: 40
Study 14679434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented group with polished Landos Fjord‐CrCo stems
Number of subjects: 14
Study 14679434 — intervention group
Group type: COMPARATOR
Intervention: Uncemented group with hydroxyapatite‐coated Landos Corail‐Titan stems
Number of subjects: 14
Study 14679434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Cemented and Uncemented)
Number of subjects: 14
Study 11128729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation at home by rehabilitation team for up to three months
Number of subjects: 43
Study 11128729 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 9377859 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol at a dose of 240 mg/day for 30 days
Number of subjects: 20
Study 9377859 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT) before beta-blockade
Number of subjects: 20
Study 9377859 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 20
Study 1543450 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% indomethacin aqueous suspension
Number of subjects: 36
Study 1543450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 36
Study 3920393 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 120
Study 3920393 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 120
Study 31259767 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HIV stigma
Number of subjects: 234
Study 31259767 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted stigma (between-subject)
Number of subjects: 234
Study 31259767 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted stigma (within-subject)
Number of subjects: 234
Study 31259767 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 234
Study 31259767 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 234
Study 29176500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cream
Number of subjects: 60
Study 29176500 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 (50 mg/d)
Number of subjects: 120
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 (10 mg/d)
Number of subjects: 120
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002/D-003 (50 mg/d of D-002 plus 10 mg/d of D-003)
Number of subjects: 120
Study 27433837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002
Number of subjects: 120
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003
Number of subjects: 120
Study 27433837 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002/D-003
Number of subjects: 120
Study 27433837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 24867622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 52
Study 24867622 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 52
Study 24867622 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention
Number of subjects: 52
Study 22998742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buspirone 15 mg and melatonin-SR 3 mg
Number of subjects: 0
Study 22998742 — intervention group
Group type: COMPARATOR
Intervention: Buspirone 15 mg monotherapy
Number of subjects: 0
Study 22998742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20648928 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron as FCM given as an i.v. bolus injection
Number of subjects: 24
Study 20648928 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24
Study 20648928 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24
Study 20648928 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg iron as FCM given as an i.v. infusion over 15 min
Number of subjects: 24
Study 20648928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18382126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker real-time RT-PCR methodology for quantification of five melanoma markers (Melan-A, gp 100, MAGE-3, MIA, tyrosinase)
Number of subjects: 65
Study 18382126 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-3 as a progression marker
Number of subjects: 65
Study 18382126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker real-time RT-PCR
Number of subjects: 65
Study 15819586 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel for 12 months after PCI with DES
Number of subjects: 0
Study 15819586 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel for 4 weeks plus aspirin after PCI with DES
Number of subjects: 0
Study 15819586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antithrombotic therapy with aspirin and clopidogrel
Number of subjects: 0
Study 14517641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 67
Study 14517641 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 67
Study 10626025 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in decision-making about testing for recurrent disease (TFR) as part of follow-up care
Number of subjects: 0
Study 9005786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ofloxacin 400 mg once a day (group I)
Number of subjects: 24
Study 9005786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ofloxacin 200 mg twice a day for 2 to 4 days followed by oral use of 400 mg once a day for 6 to 8 days (group II)
Number of subjects: 24
Study 1930700 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal ingredients in toothpaste and oral rinse
Number of subjects: 50
Study 1930700 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparations
Number of subjects: 50
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate (average daily dose 436 mg)
Number of subjects: 11
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide therapy
Number of subjects: 11
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide therapy after 1 week
Number of subjects: 11
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide therapy after 2 weeks
Number of subjects: 11
Study 7074749 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide concentrations of 200‐800 ng/ml
Number of subjects: 11
Study 7074749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 11
Study 31402072 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM-ALND
Number of subjects: 0
Study 31402072 — intervention group
Group type: COMPARATOR
Intervention: Standard-ALND
Number of subjects: 0
Study 31291207 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT program 'Good Days Ahead' with weekly guidance and support
Number of subjects: 67
Study 31291207 — intervention group
Group type: COMPARATOR
Intervention: Control condition with a freely available online CBT workbook
Number of subjects: 67
Study 31291207 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT program 'Good Days Ahead'
Number of subjects: 67
Study 29051015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention (Supporting Children's Outcomes using Rewards, Exercise and Skills) over 6 months.
Number of subjects: 1139
Study 29051015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1139
Study 25357093 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 78
Study 25357093 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 78
Study 22837541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based functional and specific balance training programme including dual-task exercises (24 training sessions over three months)
Number of subjects: 66
Study 22837541 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 66
Study 21871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant MMP‐3
Number of subjects: 0
Study 21871427 — intervention group
Group type: COMPARATOR
Intervention: MMP‐3-null mice
Number of subjects: 0
Study 21871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified MMP‐3
Number of subjects: 0
Study 21871427 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin-treated MMP‐3-null mice
Number of subjects: 0
Study 19552232 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (4.2 gm/day)
Number of subjects: 97
Study 19552232 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum (4.2 gm/day)
Number of subjects: 97
Study 19552232 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 97
Study 19552232 — intervention group
Group type: COMPARATOR
Intervention: Xylitol gum (6 months after baseline exams)
Number of subjects: 97
Study 17353581 — intervention group
Group type: COMPARATOR
Intervention: Upper tertile of diet score (mean diet score 26.3 ± 6.8 in normoglycemic, 25.7 ± 6.4 in IFG, 22.2 ± 5.8 in diabetic subjects)
Number of subjects: 3042
Study 17353581 — intervention group
Group type: COMPARATOR
Intervention: Upper tertile of diet score
Number of subjects: 3042
Study 12653894 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (150 mg) for 7 days
Number of subjects: 46
Study 12653894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12653894 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (150 mg) for 7 days in subgroup IB (n = 22)
Number of subjects: 46
Study 10591823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron orally disintegrating tablet (ondODT) 8 mg
Number of subjects: 0
Study 10591823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron orally disintegrating tablet (ondODT) 16 mg
Number of subjects: 0
Study 10591823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8877126 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) vaccine
Number of subjects: 100
Study 8877126 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-, 45-, or 135-micrograms doses of subvirion (SV) vaccine
Number of subjects: 100
Study 8877126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1816396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 97
Study 1816396 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin
Number of subjects: 97
Study 6210562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin 1 g
Number of subjects: 12
Study 6210562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin 3 g
Number of subjects: 12
Study 6210562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin 5 g
Number of subjects: 12
Study 31992258 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session continuing care telephone intervention
Number of subjects: 0
Study 31992258 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session continuing care telephone intervention
Number of subjects: 0
Study 31992258 — intervention group
Group type: COMPARATOR
Intervention: continuing care plan only
Number of subjects: 0
Study 30694322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cumulative dose, 72.5 mg/kg)
Number of subjects: 372
Study 30694322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 30694322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 372
Study 29178895 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans
Number of subjects: 221
Study 29178895 — intervention group
Group type: COMPARATOR
Intervention: Routine care plans
Number of subjects: 221
Study 25240300 — intervention group
Group type: EXPERIMENTAL
Intervention: Contagious yawning elicited through viewing videotaped yawn stimuli
Number of subjects: 14
Study 23701917 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256066 25 μg
Number of subjects: 104
Study 23701917 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256066 87.5 μg
Number of subjects: 104
Study 23701917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 21986180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate
Number of subjects: 27
Study 21986180 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate
Number of subjects: 27
Study 19595367 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Baby Interaction Programme (PBIP) sessions during neonatal intensive care unit admission and up to 6 weeks after discharge
Number of subjects: 233
Study 19595367 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 233
Study 16757200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral fluoride-releasing system (IFRS)
Number of subjects: 22
Study 16757200 — intervention group
Group type: COMPARATOR
Intervention: Stannous fluoride gel (control group)
Number of subjects: 22
Study 16757200 — intervention group
Group type: COMPARATOR
Intervention: Control group (stannous fluoride gel)
Number of subjects: 22
Study 14988783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% and tropicamide 1% eye-drops
Number of subjects: 303
Study 14988783 — intervention group
Group type: COMPARATOR
Intervention: No mydriatics
Number of subjects: 303
Study 14988783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% plus epinephrine 1/200,000
Number of subjects: 303
Study 10512253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DOA) 5 microg x kg(‐1) x min(‐1)
Number of subjects: 70
Study 10512253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (DOB) 0.5, 1, or 3 microg x kg(‐1) x min(‐1)
Number of subjects: 70
Study 10512253 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (DOA) and Dobutamine (DOB)
Number of subjects: 70
Study 7481985 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-intensity anticoagulation (INR 1.4 to 2.0)
Number of subjects: 101
Study 7481985 — intervention group
Group type: COMPARATOR
Intervention: Standard low-intensity anticoagulation (INR 2.0 to 3.0)
Number of subjects: 101
Study 1772463 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d. for 24 weeks
Number of subjects: 94
Study 1772463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 7338121 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 28
Study 7338121 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 31589066 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual processing of tetrominoes in a stream of distracting objects.
Number of subjects: 7
Study 31589066 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual processing of tetrominoes with incidental shape information.
Number of subjects: 7
Study 30680452 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Number of subjects: 200
Study 29864379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 452
Study 29864379 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 452